HPS-145 - Prescription patterns and effectiveness of Sacituzumab Govitecan in the real-world treatment of advanced breast cancer among Asian populations

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: HPS-145
• By: LIU, Ya-Chieh (Department Of Pharmacy, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, China Taiwan)
• Co-author(s): Ms Ya-Chieh Liu (Department Of Pharmacy, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan, No. 5, Fuxing St., Guishan Dist., Taoyuan City , Taiwan (r.o.c.), China Taiwan)
  Mr Kai-Cheng Chang
  Ms Hui-Yu Chen
  MD Po-Jung Su
  
• Abstract:

  Introduction
  Sacituzumab govitecan (SG) is an antibody-drug conjugate that targets the trophoblast cell surface antigen 2 (Trop-2) and has been approved for the treatment of patients with locally advanced or metastatic triple-negative breast cancer (TNBC) and hormone receptor-positive (HR+) breast cancer who have not responded well to systemic..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login